Leerink Partners Maintains Exact Sciences(EXAS.US) With Buy Rating
Exact Sciences (EXAS) Receives a Buy From Leerink Partners
Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement
Will Screening Sales Drive Exact Sciences' Q3 Earnings?
Exact Sciences Corporation (EXAS) Bounced Back in Q3
Humacyte's $30 Million Stock Offering Fuels Growth Despite Insider Concerns
Exact Sciences Corp (EXAS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
(EXAS) - Analyzing Exact Sciences's Short Interest
Exact Sciences Schedules Third Quarter 2024 Earnings Call
BTIG Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $82
Buy Rating on Exact Sciences: Anticipating Growth From Cologuard Plus and Strategic Initiatives
Leerink Partners Maintains Exact Sciences(EXAS.US) With Buy Rating, Announces Target Price $100
Sector Update: Health Care Stocks Rise Pre-Bell Friday
Express News | Exact Sciences Shares up 1.2% Premarket After FDA Approves Co's Colorectal Cancer Screening Test
Express News | Exact Sciences Corp - Cologuard Plus Test Expected to Launch With Medicare Coverage in 2025
Express News | FDA Approves Exact Sciences’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening
FDA Approves Exact Sciences' Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening
Exact Sciences Corporation's (NASDAQ:EXAS) Path To Profitability
Evercore Maintains Exact Sciences(EXAS.US) With Buy Rating, Raises Target Price to $80
Exact Sciences Price Target Raised to $80 From $72 at Evercore ISI